SITE005-0090

SITE005 (FRA) › SITE005-0090

SITE005-0090

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2025-12-21

enrolled

AEs

2

Serious

0

Dropout signal

–

Adverse events

2

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-01-23 (study day 211); relationship: RELATED

mild assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-07-30 (study day 34); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.